Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: A cross-species comparison

Journal of General Virology

Volumn 89, Issue 9, 2008, Pages 2204-2213

  Wright, Edward ^a   Temperton, Nigel J ^a   Marston, Denise A ^b   McElhinney, Lorraine M ^b   Fooks, Anthony R ^b   Weiss, Robin A ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b VETERINARY LABORATORIES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENTARY DNA; GLYCOPROTEIN; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; LUCIFERASE; NEUTRALIZING ANTIBODY; G PROTEIN, VESICULAR STOMATITIS VIRUS; MEMBRANE PROTEIN; RABIES VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ARTICLE; CELL STRAIN BHK; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; MOLECULAR CLONING; MURINE LEUKEMIA VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RABIES VIRUS; REPORTER GENE; SPECIES COMPARISON; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; ANIMAL; BAT; BIOSYNTHESIS; CAT; CELL LINE; COMPARATIVE STUDY; DOG; GENETIC TRANSFECTION; GENETICS; HAMSTER; IMMUNOLOGY; LENTIVIRINAE; MOUSE; SERODIAGNOSIS; SPECIES DIFFERENCE; VIROLOGY;

ANIMALIA; CRICETINAE; HUMAN IMMUNODEFICIENCY VIRUS; MURINE LEUKEMIA VIRUS; RABIES VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CATS; CELL LINE; CHIROPTERA; CRICETINAE; DOGS; HUMANS; LENTIVIRUS; LYSSAVIRUS; MEMBRANE GLYCOPROTEINS; MICE; NEUTRALIZATION TESTS; RABIES VACCINES; RABIES VIRUS; SPECIES SPECIFICITY; TRANSFECTION; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS;

EID: 52649104801     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.2008/000349-0     Document Type: Article

References (36)

1. Badrane, H., Bahloul, C., Perrin, P. & Tordo, N. (2001). Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 75, 3268-3276.
2. Bartosch, B., Bukh, J., Meunier, J. C., Granier, C., Engle, R. E., Blackwelder, W. C., Emerson, S. U., Cosset, F. L. & Purcell, R. H. (2003). In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 100, 14199-14204.
3. Bresson, J. L., Perronne, C., Launay, O., Gerdil, C., Saville, M., Wood, J., Hoschler, K. & Zambon, M. C. (2006). Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/ 2004 (H5N1) vaccine: phase I randomised trial. Lancet 367, 1657-1664.
4. Brookes, S. M., Parsons, G., Johnson, N., McElhinney, L. M. & Fooks, A. R. (2005). Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 23, 4101-4109.
5. Clapham, P., Nagy, K. & Weiss, R. A. (1984). Pseudotypes of human T-cell leukemia virus types 1 and 2: neutralization by patients' sera. Proc Natl Acad Sci U S A 81, 2886-2889.
6. Cliquet, F., Aubert, M. & Sagne, L. (1998). Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 212, 79-87.
7. Cliquet, F., McElhinney, L. M., Servat, A., Boucher, J. M., Lowings, J. P., Goddard, T., Mansfield, K. L. & Fooks, A. R. (2004). Development of a qualitative indirect ELISA for the measurement of rabies virus-specific antibodies from vaccinated dogs and cats. J Virol Methods 117, 1-8.
8. Condit, R. C. (2001). Principles of Virology. In Fields Virology, 4th edn, vol. 1, pp. 19-51. Edited by D. M. Knipe & P. M. Howley. Philadelphia: Lippincott Williams & Wilkins.
9. Cox, J. H., Dietzschold, B. & Schneider, L. G. (1977). Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun 16, 754-759.
10. Cox, R. J., Mykkeltvedt, E., Robertson, J. & Haaheim, L. R. (2002). Non-lethal viral challenge of influenza haemagglutinin and nucleo-protein DNA vaccinated mice results in reduced viral replication. Scand J Immunol 55, 14-23.
11. Dalgleish, A. G., Beverley, P. C., Clapham, P. R., Crawford, D. H., Greaves, M. F. & Weiss, R. A. (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312, 763-767.
12. Demaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M. & Thrasher, A. J. (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13, 803-813.
13. Desmaris, N., Bosch, A., Salaun, C., Petit, C., Prevost, M. C., Tordo, N., Perrin, P., Schwartz, O., de Rocquigny, H. & other authors (2001). Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol Ther 4, 149-156.
14. Dietzschold, B., Lafon, M., Wang, H., Otvos, L., Jr, Celis, E., Wunner, W. H. & Koprowski, H. (1987). Localization and immunological characterization of antigenic domains of the rabies virus internal N and NS proteins. Virus Res 8, 103-125.
15. DuBridge, R. B., Tang, P., Hsia, H. C., Leong, P. M., Miller, J. H. & Calos, M. P. (1987). Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7, 379-387.
16. Fooks, A. (2004). The challenge of new and emerging lyssaviruses. Expert Rev Vaccines 3, 333-336.
17. Fooks, A. R. (2005). Rabies remains a 'neglected disease'. Euro Surveill 10, 211-212.
18. Fooks, A. R., Brookes, S. M., Johnson, N., McElhinney, L. M. & Hutson, A. M. (2003). European bat lyssaviruses: an emerging zoonosis. Epidemiol Infect 131, 1029-1039.
19. Hanlon, C. A., Kuzmin, I. V., Blanton, J. D., Weldon, W. C., Manangan, J. S. & Rupprecht, C. E. (2005). Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res 111, 44-54.
20. Khawplod, P., Inoue, K., Shoji, Y., Wilde, H., Ubol, S., Nishizono, A., Kurane, I. & Morimoto, K. (2005). A novel rapid fluorescent focus inhibition test for rabies virus using a recombinant rabies virus visualizing a green fluorescent protein. J Virol Methods 125, 35-40.
21. Mallewa, M., Fooks, A. R., Banda, D., Chikungwa, P., Mankhambo, L., Molyneux, E., Molyneux, M. E. & Solomon, T. (2007). Rabies encephalitis in malaria-endemic area, Malawi, Africa. Emerg Infect Dis 13, 136-139.
22. Mazarakis, N. D., Azzouz, M., Rohll, J. B., Ellard, F. M., Wilkes, F. J., Olsen, A. L., Carter, E. E., Barber, R. D., Baban, D. F. & other authors (2001). Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 10, 2109-2121.
23. Mentis, G. Z., Gravell, M., Hamilton, R., Shneider, N. A., O'Donovan, M. J. & Schubert, M. (2006). Transduction of motor neurons and muscle fibers by intramuscular injection of HIV-1-based vectors pseudotyped with select rabies virus glycoproteins. J Neurosci Methods 157, 208-217.
24. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M. & Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
25. Op De Beeck, A., Voisset, C., Bartosch, B., Ciczora, Y., Cocquerel, L., Keck, Z., Foung, S., Cosset, F. L. & Dubuisson, J. (2004). Characterization of functional hepatitis C virus envelope glycoproteins. J Virol 78, 2994-3002.
26. Soda, Y., Shimizu, N., Jinno, A., Liu, H. Y., Kanbe, K., Kitamura, T. & Hoshino, H. (1999). Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 258, 313-321.
27. Stoker, M. & Macpherson, I. (1964). Syrian hamster fibroblast cell line BHK21 and its derivatives. Nature 203, 1355-1357.
28. Stratton, M. R., Darling, J., Pilkington, G. J., Lantos, P. L., Reeves, B. R. & Cooper, C. S. (1989). Characterization of the human cell line TE671. Carcinogenesis 10, 899-905.
29. Takeuchi, Y., Porter, C. D., Strahan, K.M., Preece, A. F., Gustafsson, K., Cosset, F. L., Weiss, R. A. & Collins, M. K. (1996). Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 379, 85-88.
30. Temperton, N. J., Chan, P. K., Simmons, G., Zambon, M. C., Tedder, R. S., Takeuchi, Y. & Weiss, R. A. (2005). Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis 11, 411-416.
31. Temperton, N. J., Hoschler, K., Major, D., Nicolson, C., Manvell, R., Hien, V. M., Ha, D. Q., Jong, M. D., Zambon, M. & other authors (2007). A sensitive retroviral pseudotype assay for influenza H5N1- neutralizing antibodies. Influenza Resp Viruses 1, 105-112.
32. Towers, G. J. (2007). The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4: 40.
33. Towers, G., Bock, M., Martin, S., Takeuchi, Y., Stoye, J. P. & Danos, O. (2000). A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A 97, 12295-12299.
34. WHO (2006). Rabies. Fact Sheet No. 99. Geneva, World Helath Organisation.
35. Wool-Lewis, R. J. & Bates, P. (1998). Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 72, 3155-3160.
36. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15, 871-875.